Arcus Biosciences (RCUS) Prices 11M Share Common Offering at $27.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Arcus Biosciences (RCUS) Commences Underwritten Public Offering of Common Stock
May 27, 2020 4:46 PM EDTArcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that it has commenced an underwritten public offering of its common stock. The company intends to grant the underwriters a 30-day option to purchase up... More
Arcus Biosciences (RCUS) PT Raised to $48 at Wedbush, Following Important Business Update
May 27, 2020 2:18 PM EDTWedbush analyst Robert Driscoll raised the price target on Arcus Biosciences (NYSE: RCUS) to $48.00 (from $40.00) while maintaining a Outperform rating.
... MorePre-Open Stock Movers 05/27: (HTZ) (PHUN) (MRSN) (STNE) (CPIX) (HTBX) (SAVE) (more...)
May 27, 2020 8:44 AM EDTToday's Pre-Open Stock Movers:
Hertz Global Holdings, Inc. (NYSE: HTZ) +58%; announced over the weekend it and certain of its U.S. and Canadian subsidiaries have filed voluntary petitions for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Phunware (NASDAQ: PHUN) +38%; announced today its strategic relationship with American Made Media Consultants on the development, launch and ongoing management and evolution of the Trump-Pence... More
Gilead Sciences (GILD), Arcus Biosciences (RCUS) Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies
May 27, 2020 7:12 AM EDTGilead Sciences, Inc. (NASDAQ: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapeutics, announced today that the companies have entered into a 10-year partnership to co-develop and co-commercialize current and future therapeutic product candidates in Arcuss pipeline. The agreement will also provide ongoing funding to support Arcuss research and development programs.
Arcus is building an extensive and diverse portfolio of investigational products that target important mechanisms involved in tumor evasion of the immune system, as well as developing drug candidates... More
